Summary Four human cell lines derived from malignant gliomas were immunohistochemically examined for their content of estramustine-binding protein (EMBP). EMBP was detected in a large amount in all glioma cells during the entire cell cycle. EMBP has previously been demonstrated to be the major receptor protein in prostatic cancers for the cytostatic drug estramustine-phosphate (EMP). EMP caused a dose-dependent inhibition of exponentially growing cells by increasing the number of cells in G2/M stage of the cell cycle as monitored by flow cytofluorometry. The effect may be coupled to arrest of the glioma cells at metaphase. The presence of EMBP may suggest a selective binding and effect of EMP in glioma cells.
Summary Four human cell lines derived from malignant gliomas were immunohistochemically examined for their content of estramustine-binding protein (EMBP). EMBP was detected in a large amount in all glioma cells during the entire cell cycle. EMBP has previously been demonstrated to be the major receptor protein in prostatic cancers for the cytostatic drug estramustine-phosphate (EMP). EMP caused a dose-dependent inhibition of exponentially growing cells by increasing the number of cells in G2/M stage of the cell cycle as monitored by flow cytofluorometry. The effect may be coupled to arrest of the glioma cells at metaphase. The presence of EMBP may suggest a selective binding and effect of EMP in glioma cells.
Estramustine phosphate (EMP), a cytotoxic nornitrogenmustard derivate of estradiol-1 7,B-phosphate, is generally accepted in the treatment of advanced prostatic carcinoma (Madajewics et al., 1980) . Estramustine phosphate is dephosphorylated in the gastrointestinal tract to estramustine, which to a high extent is oxidized to estromustine (Andersson et al., 1981) . The exact mechanism of action by EMP on malignant tissue is incompletely understood. EMP has been shown to induce mitotic arrest in human prostatic cancer cell lines by interaction with the mitotic spindle (Hartley-Asp, 1984) . Recently EMP was found to generate free oxygen-radicals (Grankvist et al., 1988) .
The presence of a specific binding protein, estramustine binding protein (EMBP), could be important for the effect. EMBP has been demonstrated in prostatic cancer tissue cytosol from rat and man (Bjork et al., 1982) . EMBP, which is distinct from the estrogen receptor, binds estramustine and the main metabolite estromustine with high affinity, and thus may be important for drug action in malignant target tissue (Forsgren et al., 1979b; Bjork et al., 1985) .
In this report we demonstrate the presence of EMBP in cultured human malignant glioma cell lines by an immunohistochemical method using mouse monoclonal antibodies with cross-reactivity to the human counterpart (Bergh et al., submitted; Nilsson et al., submitted) . Furthermore, the effects of EMP on cellular growth were examined.
Materials and methods
Cell culture Four human glioma cell lines (U-251 MG, U-118 MG, U-105 MG, U-87 MG) were used (Westermark et al., 1973 Immunohistochemical demonstration of EMBP Malignant glioma cells from stock cultures (see above) were washed in PBS three times and spun down at 500 g for 10min. The pellets were snap frozen at -70°C, followed by freeze sectioning at time of use. The cells were then analyzed for the presence of EMBP using the conventional indirect antibody-peroxidase technique. The techniques have been described in detail elsewhere (Sternberger, 1979; Bergh et al., 1985a) .
Endogenous peroxidase activity was blocked by addition of H202 in methanol. The primary mouse monoclonal antibody (Mab EMBP 1) raised against purified rat EMBP, with demonstrated cross-reactivity to human EMBP (Bergh et al., 1988) , was added diluted 1/10 to the sections for 1-1 h. After sequential washings in PBS the rabbit anti mouse avidin-biotin peroxidase antiperoxidase complexes (Vectastain, Burlingame, California, USA) were added. The staining reaction was developed in DMSO/ethylcarbozole, followed by counterstaining with haemathoxylin and mounting in glycerol-gelatin. Two small cell lung cancer cell lines U-1285 and U-1906 (Bergh et al., 1985b) were used as negative and positive controls respectively. U-1285 has previously been demonstrated to contain only minute amounts of EMBP using fast-protein liquid chromatography, whereas U-1906 has been shown to exhibit large amounts (Bergh et al., submitted) . Furthermore, for each tested cell line -another negative control was obtained by omitting the primary monoclonal antibody. Immunohistochemical staining results were semiquantitatively analyzed according to the scheme in Table I . Br. J. Canc-er (1988), 58, 326-329 (Figures 1 and 2 ). EMP caused a dose-dependent inhibition of growth of all three cell lines tested in the concentration range 1-40pgml-'. All cell lines were maximally inhibited by 20 pgml-1EMP during 6 days incubation. There was a small difference in the sensitivity of the different cell lines with U-18-MG being the most sensitive. In all investigated cell lines the inhibitory effect of EMP was reversed by washing and reincubation in fresh medium. Figure 3 illustrates the reversal of the inhibitory effect even in a rather high concentration of 20 ,g ml 1EMP on U-105 MG cells.
Effect on cell cycle To examine whether a block existed in a certain cell cycle phase, cell cycle parameters were studied by cytofluorometry. Estramustine phosphate treatment for 3 days caused a large increase in the number of cells in G2/M compared to controls (Figure 4 , Table II ). Consequently this diminished the proportion of GO/GI cells. Estramustine did not seem to block cells in a resting Go stage. All cells also had the morphological characteristics of mitotic cells (Figure 2b ). Discussion EMBP has been described as a major androgen dependent secretory protein in the rat ventral prostate (Pousette et al., 1981) . It is distinct from the estrogen receptor, has a low affinity for estrogens but binds estramustine with a dissociation constant (Kd) of 2 x 10 -8 M (Forsgren et al., 1979b , Bjork et al., 1985 . A human analogue to this protein has been demonstrated in normal benign hyperplastic and U-118MG, (c) U-251 MG. O=control, * =5pg/ml-1, A=/10jg/ml-1, *=20pg/ml-1. malignant prostatic tissue (Bjork et al., 1982 ) and suggested to act as an accumulator of estramustine and estromustine during clinical therapy (Bjork et al., 1985) . EMBP was originally identified when looking for the mechanism of action by estramustine phosphate (EMP), a drug which is accepted in the treatment of advanced prostatic carcinoma. In the present study we demonstrate for the first time the presence of EMBP in human glioma cell lines and that EMP has the capacity of inhibiting the growth of glioma cells in vitro.
The mouse monoclonal antibody (Mab EMBP-1) used here, raised against purified rat EMBP displays a significant reactivity with human tissues previously demonstrated to be positive with the polyclonal rabbit antiserum to EMBP (Forsgren et al., 1979a , Bjork et al., 1982 . Significant interspecies immunoreactivities have also been demonstrated together with specific staining with the Mab EMBP-1 in normal human prostatic epithelium and prostatic carcinomas , Bergh et al., 1988 .
Previously EMBP has been detected in the pituitary gland and cerebral cortex of male and female rats (Forsgren et al., 1979a) . While the biological role of this glycoprotein within the CNS remains to be elucidated its presence of EMBP in glioma cells may have a clinical interest in the management of malignant gliomas. As previously demonstrated in the rat (Bjork et al., 1982) The cytotoxic effect of EMP is believed to be mediated by a direct action of the main metabolites estramustine and estromustine (Bjork et al., 1985) . Mitotic arrest and inhibition of DNA synthesis were more pronounced by the estramustine complex than for the nor-nitrogen mustard alone (Hartley-Asp et al., 1982; Hartley-Asp, 1984; Bjork et al., 1985) . In our in vitro system it is difficult to state which of the components is responsible for the growth-inhibition of glioma cells.
In the present cell cultures the effect was clearly dosedependent and maximal inhibition was achieved at concentrations from 10-20 ug ml -. Using these concentrations exponentially growing glioma cells were accumulated in the G2/M stage and the fraction of G1/GO, was reduced. These data are in good agreement with previous studies on various prostatic cancer cell lines (Hartley-Asp et al., 1982) and cell lines of small cell lung cancer (Westlin et al., unpublished results). Moreover, the effects of EMP seemed to be reversible. However, the possibility also exists that fully sensitive cells do not regrow. This would be the effect if the used cells were not from a pure clonal cell line. The exact mechanism for this interaction between EMP and tumour cells is unknown but has recently been suggested to involve free oxygen radicals (Grankvist et al., 1988) .
In conclusion, a protein with immunohistochemical characteristics related to EMBP has been demonstrated for the first time in human malignant glioma cells. The physiological significance of this observation remains to be elucidated. EMBP has been proposed to participate in the mechanism for a specific binding of the metabolites of EMP (Bjork et al., 1985) . Detection of EMBP in tumour cells could possibly be of future value for the selection of patients that may benefit from EMP treatment. Further studies on the mechanism of action of EMP and it's specific binding protein within the CNS are certainly justified.
